No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism : Pooled Results From 2 Randomized Controlled Trials. / Du Puy, Robert S.; Poortvliet, Rosalinde K. E.; Mooijaart, Simon P.; Stott, David J.; Quinn, Terry; Sattar, Naveed; Westendorp, Rudi G. J.; Kearney, Patricia M.; McCarthy, Vera J. C.; Byrne, Stephen; Rodondi, Nicolas; Baretella, Oliver; Collet, Tinh-Hai; van Heemst, Diana; Dekkers, Olaf M.; Jukema, J. Wouter; Smit, Johannes W. A.; Gussekloo, Jacobijn; den Elzen, Wendy P. J.

In: Journal of Clinical Endocrinology & Metabolism, Vol. 107, 2022, p. e2339–e2347.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Du Puy, RS, Poortvliet, RKE, Mooijaart, SP, Stott, DJ, Quinn, T, Sattar, N, Westendorp, RGJ, Kearney, PM, McCarthy, VJC, Byrne, S, Rodondi, N, Baretella, O, Collet, T-H, van Heemst, D, Dekkers, OM, Jukema, JW, Smit, JWA, Gussekloo, J & den Elzen, WPJ 2022, 'No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials', Journal of Clinical Endocrinology & Metabolism, vol. 107, pp. e2339–e2347. https://doi.org/10.1210/clinem/dgac106

APA

Du Puy, R. S., Poortvliet, R. K. E., Mooijaart, S. P., Stott, D. J., Quinn, T., Sattar, N., Westendorp, R. G. J., Kearney, P. M., McCarthy, V. J. C., Byrne, S., Rodondi, N., Baretella, O., Collet, T-H., van Heemst, D., Dekkers, O. M., Jukema, J. W., Smit, J. W. A., Gussekloo, J., & den Elzen, W. P. J. (2022). No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials. Journal of Clinical Endocrinology & Metabolism, 107, e2339–e2347. https://doi.org/10.1210/clinem/dgac106

Vancouver

Du Puy RS, Poortvliet RKE, Mooijaart SP, Stott DJ, Quinn T, Sattar N et al. No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials. Journal of Clinical Endocrinology & Metabolism. 2022;107:e2339–e2347. https://doi.org/10.1210/clinem/dgac106

Author

Du Puy, Robert S. ; Poortvliet, Rosalinde K. E. ; Mooijaart, Simon P. ; Stott, David J. ; Quinn, Terry ; Sattar, Naveed ; Westendorp, Rudi G. J. ; Kearney, Patricia M. ; McCarthy, Vera J. C. ; Byrne, Stephen ; Rodondi, Nicolas ; Baretella, Oliver ; Collet, Tinh-Hai ; van Heemst, Diana ; Dekkers, Olaf M. ; Jukema, J. Wouter ; Smit, Johannes W. A. ; Gussekloo, Jacobijn ; den Elzen, Wendy P. J. / No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism : Pooled Results From 2 Randomized Controlled Trials. In: Journal of Clinical Endocrinology & Metabolism. 2022 ; Vol. 107. pp. e2339–e2347.

Bibtex

@article{24221d05a13a418c9a3be860d1c700af,
title = "No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials",
abstract = "Context Subclinical thyroid dysfunction and anemia are common disorders, and both have increasing prevalence with advancing age. Objective The aim of this study was to assess whether levothyroxine treatment leads to a rise in hemoglobin levels in older persons with subclinical hypothyroidism. Methods This preplanned combined analysis of 2 randomized controlled trials included community-dwelling persons aged 65 years and older with subclinical hypothyroidism who were randomly assigned to levothyroxine or placebo treatment. The levothyroxine dose was periodically titrated aiming at thyroid stimulating hormone (TSH) level within the reference range, with mock titrations in the placebo group. The main outcome measure was the change in hemoglobin level after 12 months. Results Analyses included 669 participants (placebo n = 337, levothyroxine n = 332) with a median age of 75 years (range, 65-97) and mean baseline hemoglobin of 13.8 +/- 1.3 g/dL. Although levothyroxine treatment resulted in a reduction in TSH from baseline after 12 months of follow-up compared with placebo, the change in hemoglobin level was not different between the levothyroxine and the placebo groups (-0.03 g/dL [95% CI, -0.16 to 0.11]). Similar results were found in stratified analyses including sex, age, or TSH levels. No difference in change of hemoglobin levels after 12 months was identified in 69 participants with anemia at baseline (-0.33 g/dL [95% CI, -0.87 to 0.21]). Conclusion In persons aged 65 years and older with subclinical hypothyroidism, treatment with levothyroxine does not lead to a rise in hemoglobin levels, regardless of the presence of anemia.",
keywords = "thyroid, anemia, RCT, subclinical hypothyroidism, older adults, THYROID-DYSFUNCTION, ANEMIA, ERYTHROPOIESIS, HORMONES, RISK",
author = "{Du Puy}, {Robert S.} and Poortvliet, {Rosalinde K. E.} and Mooijaart, {Simon P.} and Stott, {David J.} and Terry Quinn and Naveed Sattar and Westendorp, {Rudi G. J.} and Kearney, {Patricia M.} and McCarthy, {Vera J. C.} and Stephen Byrne and Nicolas Rodondi and Oliver Baretella and Tinh-Hai Collet and {van Heemst}, Diana and Dekkers, {Olaf M.} and Jukema, {J. Wouter} and Smit, {Johannes W. A.} and Jacobijn Gussekloo and {den Elzen}, {Wendy P. J.}",
year = "2022",
doi = "10.1210/clinem/dgac106",
language = "English",
volume = "107",
pages = "e2339–e2347",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism

T2 - Pooled Results From 2 Randomized Controlled Trials

AU - Du Puy, Robert S.

AU - Poortvliet, Rosalinde K. E.

AU - Mooijaart, Simon P.

AU - Stott, David J.

AU - Quinn, Terry

AU - Sattar, Naveed

AU - Westendorp, Rudi G. J.

AU - Kearney, Patricia M.

AU - McCarthy, Vera J. C.

AU - Byrne, Stephen

AU - Rodondi, Nicolas

AU - Baretella, Oliver

AU - Collet, Tinh-Hai

AU - van Heemst, Diana

AU - Dekkers, Olaf M.

AU - Jukema, J. Wouter

AU - Smit, Johannes W. A.

AU - Gussekloo, Jacobijn

AU - den Elzen, Wendy P. J.

PY - 2022

Y1 - 2022

N2 - Context Subclinical thyroid dysfunction and anemia are common disorders, and both have increasing prevalence with advancing age. Objective The aim of this study was to assess whether levothyroxine treatment leads to a rise in hemoglobin levels in older persons with subclinical hypothyroidism. Methods This preplanned combined analysis of 2 randomized controlled trials included community-dwelling persons aged 65 years and older with subclinical hypothyroidism who were randomly assigned to levothyroxine or placebo treatment. The levothyroxine dose was periodically titrated aiming at thyroid stimulating hormone (TSH) level within the reference range, with mock titrations in the placebo group. The main outcome measure was the change in hemoglobin level after 12 months. Results Analyses included 669 participants (placebo n = 337, levothyroxine n = 332) with a median age of 75 years (range, 65-97) and mean baseline hemoglobin of 13.8 +/- 1.3 g/dL. Although levothyroxine treatment resulted in a reduction in TSH from baseline after 12 months of follow-up compared with placebo, the change in hemoglobin level was not different between the levothyroxine and the placebo groups (-0.03 g/dL [95% CI, -0.16 to 0.11]). Similar results were found in stratified analyses including sex, age, or TSH levels. No difference in change of hemoglobin levels after 12 months was identified in 69 participants with anemia at baseline (-0.33 g/dL [95% CI, -0.87 to 0.21]). Conclusion In persons aged 65 years and older with subclinical hypothyroidism, treatment with levothyroxine does not lead to a rise in hemoglobin levels, regardless of the presence of anemia.

AB - Context Subclinical thyroid dysfunction and anemia are common disorders, and both have increasing prevalence with advancing age. Objective The aim of this study was to assess whether levothyroxine treatment leads to a rise in hemoglobin levels in older persons with subclinical hypothyroidism. Methods This preplanned combined analysis of 2 randomized controlled trials included community-dwelling persons aged 65 years and older with subclinical hypothyroidism who were randomly assigned to levothyroxine or placebo treatment. The levothyroxine dose was periodically titrated aiming at thyroid stimulating hormone (TSH) level within the reference range, with mock titrations in the placebo group. The main outcome measure was the change in hemoglobin level after 12 months. Results Analyses included 669 participants (placebo n = 337, levothyroxine n = 332) with a median age of 75 years (range, 65-97) and mean baseline hemoglobin of 13.8 +/- 1.3 g/dL. Although levothyroxine treatment resulted in a reduction in TSH from baseline after 12 months of follow-up compared with placebo, the change in hemoglobin level was not different between the levothyroxine and the placebo groups (-0.03 g/dL [95% CI, -0.16 to 0.11]). Similar results were found in stratified analyses including sex, age, or TSH levels. No difference in change of hemoglobin levels after 12 months was identified in 69 participants with anemia at baseline (-0.33 g/dL [95% CI, -0.87 to 0.21]). Conclusion In persons aged 65 years and older with subclinical hypothyroidism, treatment with levothyroxine does not lead to a rise in hemoglobin levels, regardless of the presence of anemia.

KW - thyroid

KW - anemia

KW - RCT

KW - subclinical hypothyroidism

KW - older adults

KW - THYROID-DYSFUNCTION

KW - ANEMIA

KW - ERYTHROPOIESIS

KW - HORMONES

KW - RISK

U2 - 10.1210/clinem/dgac106

DO - 10.1210/clinem/dgac106

M3 - Journal article

C2 - 35218666

VL - 107

SP - e2339–e2347

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

ER -

ID: 301626802